Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?
Lowe
Gordon D O
GD
University Department of Medicine, Royal Infirmary, Glasgow G31 2ER, UK. gdl1j@clinmed.gla.ac.uk
Sandercock
Peter A G
PA
Rosendaal
Frits R
FR
D000925:Anticoagulants / Q000627:therapeutic use*; D019643:Arthroplasty, Replacement; D002986:Clinical Trials as Topic / Q000592:standards; D000077425:Fondaparinux; D006801:Humans; D019637:Orthopedic Procedures; D015207:Osteoarthritis, Hip / Q000601:surgery; D020370:Osteoarthritis, Knee / Q000601:surgery; D011134:Polysaccharides / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D012107:Research Design / Q000592:standards; D013923:Thromboembolism / Q000517:prevention & control*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D011134:Polysaccharides; D000077425:Fondaparinux